Paul Tudor Jones's NBIX Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 19,524 shares of Neurocrine Biosciences, Inc. (NBIX) worth $2.77 M, representing 0.01% of the portfolio. First purchased in 2013-Q3, this long-term strategic position has been held for 34 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in NBIX, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2023, adding 48,819 shares. Largest reduction occurred in Q4 2023, reducing 45,245 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Neurocrine Biosciences (NBIX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Neurocrine Biosciences (NBIX) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -7,336 | Reduce 27.31% | 19,524 | $141.83 |
| Q3 2025 | +23,893 | Add 805.29% | 26,860 | $140.38 |
| Q2 2025 | +2,967 | New Buy | 2,967 | $125.69 |
| Q1 2024 | -3,574 | Sold Out | 0 | $0.00 |
| Q4 2023 | -45,245 | Reduce 92.68% | 3,574 | $131.76 |
| Q3 2023 | +48,819 | New Buy | 48,819 | $112.50 |
| Q2 2023 | -5,016 | Sold Out | 0 | $0.00 |
| Q1 2023 | -43,036 | Reduce 89.56% | 5,016 | $0.10 |
| Q4 2022 | +48,052 | New Buy | 48,052 | $0.12 |
| Q3 2022 | -42,694 | Sold Out | 0 | $0.00 |
| Q2 2022 | +39,675 | Add 1314.18% | 42,694 | $97.48 |
| Q1 2022 | -41,521 | Reduce 93.22% | 3,019 | $93.74 |
| Q4 2021 | +15,028 | Add 50.92% | 44,540 | $85.16 |
| Q3 2021 | +5,452 | Add 22.66% | 29,512 | $95.89 |
| Q2 2021 | +24,060 | New Buy | 24,060 | $97.34 |
| Q1 2021 | -26,854 | Sold Out | 0 | $0.00 |
| Q4 2020 | -11,898 | Reduce 30.70% | 26,854 | $95.85 |
| Q3 2020 | +38,752 | New Buy | 38,752 | $96.15 |
| Q1 2020 | -28,537 | Sold Out | 0 | $0.00 |
| Q4 2019 | +25,377 | Add 803.07% | 28,537 | $107.47 |
| Q3 2019 | +3,160 | New Buy | 3,160 | $90.19 |
| Q2 2019 | -10,419 | Sold Out | 0 | $0.00 |
| Q1 2019 | -10,739 | Reduce 50.76% | 10,419 | $88.11 |
| Q4 2018 | -2,000 | Reduce 8.64% | 21,158 | $71.42 |
| Q3 2018 | +23,158 | New Buy | 23,158 | $122.94 |
| Q2 2018 | -8,941 | Sold Out | 0 | $0.00 |
| Q1 2018 | -19,927 | Reduce 69.03% | 8,941 | $82.88 |
| Q4 2017 | +28,868 | New Buy | 28,868 | $77.59 |
| Q3 2017 | -5,428 | Sold Out | 0 | $0.00 |
| Q2 2017 | +5,428 | New Buy | 5,428 | $46.06 |
| Q2 2015 | -6,635 | Sold Out | 0 | $0.00 |
| Q1 2015 | +6,635 | New Buy | 6,635 | $39.64 |
| Q4 2013 | -30,900 | Sold Out | 0 | $0.00 |
| Q3 2013 | +30,900 | New Buy | 30,900 | $11.33 |
Paul Tudor Jones's Neurocrine Biosciences Investment FAQs
Paul Tudor Jones first purchased Neurocrine Biosciences, Inc. (NBIX) in Q3 2013, acquiring 30,900 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Neurocrine Biosciences, Inc. (NBIX) for 34 quarters since Q3 2013.
Paul Tudor Jones's largest addition to Neurocrine Biosciences, Inc. (NBIX) was in Q3 2023, adding 48,819 shares worth $5.49 M.
According to the latest 13F filing for Q4 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 19,524 shares of Neurocrine Biosciences, Inc. (NBIX), valued at approximately $2.77 M.
As of the Q4 2025 filing, Neurocrine Biosciences, Inc. (NBIX) represents approximately 0.01% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Neurocrine Biosciences, Inc. (NBIX) was 48,819 shares, as reported at the end of Q3 2023.